Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity - Wikidata - awgldk - TriplyDB

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

http://www.wikidata.org/entity/Q34608317

about

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy New developments in the genetics, pathogenesis, and therapy of IgA nephropathy Current Understanding of the Role of Complement in IgA Nephropathy The pathophysiology of IgA nephropathy The kinetics of glomerular deposition of nephritogenic IgA Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency.Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura.Expression of Acid-Sensing Ion Channels in Renal Tubular Epithelial Cells and Their Role in Patients with Henoch-Schönlein Purpura Nephritis A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.O-linked glycosylation determines the nephritogenic potential of IgA rheumatoid factor.Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy.The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1 The genetics and immunobiology of IgA nephropathy.The role of mucin-type O-glycans in eukaryotic development Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.Genetic studies of IgA nephropathy: past, present, and future.Corticosteroid therapy in IgA nephropathy.Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation.Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy.Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability.Increased plasma sVCAM-1 is associated with severity in IgA nephropathy.Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy.Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing.N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy.Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy.Development of Animal Models of Human IgA Nephropathy IgA nephropathy caused by unusual polymerization of IgA1 with aberrant N-glycosylation in a patient with monoclonal immunoglobulin deposition disease.Mapping novel immunogenic epitopes in IgA nephropathy Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy.Immune profile of IgA-dominant diffuse proliferative glomerulonephritis.Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy.IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy Profiling of autoantibodies in IgA nephropathy, an integrative antibiomics approach.

P2860

Q26752555-5A04B057-6F16-4F7E-B853-856D46B21386 Q26786248-0F7D501C-4FCA-4980-A883-2F1C3A6A6C09 Q26852163-BB1ADAB0-2A82-4EFC-9AA1-F73996CAB9C3 Q27023866-ED536C6E-7E9D-49A6-B522-13FE766DBDC9 Q27325252-0FF943A8-9527-4FE1-BCDA-2F03B9E9B87F Q28539595-9A5A0798-0E63-4F93-9F53-E5712F7A2135 Q28554822-4214D6E4-C1DC-41FA-B4A4-021591D23E1D Q33398196-434ACFC2-A617-408B-9323-30956142BE9B Q33597083-630151F5-AF7F-4D69-92FC-A81EC9C69BAA Q33613969-69089F97-D186-40EB-AEB6-D5B35062865E Q33654763-B7F69162-114A-437D-897F-2DA77561017B Q33660620-A49C451F-6077-4432-B304-C5B18D11F106 Q33780876-A2C996DC-90D8-41BC-A943-8B1888F7F941 Q33787385-5521E47A-4937-42EB-9457-0B6D0C29FBEF Q33812834-40AFC754-B38D-4F20-814A-2C65D5369FE9 Q33872517-ED01F4B3-41BF-460F-B231-AFC6F80360E8 Q33987647-DCD39343-1293-48CE-B040-79D3D624EC50 Q34088820-CEE0BE9E-4120-47D0-97BC-85634E72710F Q34109845-58C6918C-3AD8-44C6-B7E0-7D5AF5EBF4D2 Q34249313-D51B1BF8-4B64-48F2-9D48-CD07A0B106B1 Q34320745-E7E21511-E967-457F-8F03-AD1429AAF2CC Q34324220-2D735708-62E4-4E4B-97CC-CDD9C793032F Q34405441-F902FAF4-9D88-41CC-885E-759A09F81F51 Q34556089-906F22C8-90AC-460A-A2BB-DD762D9269D4 Q34557198-FBA166A0-DAF8-4944-A553-FEC25FBB8C94 Q34674784-0C95D6A8-E7EA-4C32-B8A0-E3DA4EFE2F3C Q34869928-180ACE13-D3F8-4C48-BE84-411553B05261 Q35022256-641460C0-62F8-437F-91DD-6E53B6F4A67F Q35101639-66D07D8C-9DE3-43B9-9E0D-FC2E213C9FDF Q35107938-17071947-0732-4CAF-A1D7-3CA316807ECF Q35110061-C02E438F-A11E-45A9-8DCF-A46F4E046B81 Q35126705-B5EBADA3-C26A-4169-9C01-079D2A33400A Q35144385-BB2EDB36-612F-43C8-A443-D4CA2BA64E0A Q35151900-2487730A-94A8-47B9-B268-931F8ADB22C2 Q35165506-4DB7396F-10C6-4589-979A-766AFCBEFFCB Q35232158-9CC674BA-0314-4733-B6CD-D6F0FDB238BF Q35369982-4FDF1DD8-9ED6-4D4B-AB08-7F12D934818A Q35468711-E917D5D4-464A-43D8-BE17-7BD93284F9DC Q35550560-FF6E2B7A-6A85-401E-AD81-05EFD13590F6 Q35664622-889B5CE9-BF2B-4EE4-9FA4-27E650BFE18D

P2860

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

http://www.wikidata.org/entity/Q34608317

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@ast

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@en

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@nl

type

label

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@ast

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@en

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@nl

prefLabel

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@ast

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@en

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@nl

P1433

Q34608317-D6C4D166-60EB-48EF-AC79-96475A385D2E

P1476

Q34608317-2514656B-A95F-4D68-89D2-5F12C6B81881

P2093

Q34608317-12B8A6FF-50F3-440A-B3CF-7DE5E1964711

Q34608317-1471A1FF-C15B-466A-9E05-111C40CE5EB9

Q34608317-1E59A42E-1969-4EE0-90C6-2E0884DEFA1E

Q34608317-2A600E55-EAD9-439A-B7FC-C74A888F6146

Q34608317-2DD43399-4C52-46B8-B00D-64DF94FC40A0

Q34608317-35BFF7F1-70F6-410E-A49A-FE6946AC78AE

Q34608317-4928997C-3B99-481F-B72D-F69AB04FB03E

Q34608317-4F7AEE18-111B-4EA1-94E7-6D4AA45F238F

Q34608317-66919E41-C221-4CFA-AB79-DEA9BBFCE3EF

Q34608317-7732329B-6273-4893-B31D-01971F418A3F

P2860

Q34608317-041BD70B-2024-492A-83BC-4E3ADD878D8C

Q34608317-15D23BD2-A679-4F39-BD33-2422C640F052

Q34608317-16F00103-D509-42CE-A686-DFDF78FE5096

Q34608317-177ACE43-204B-4BF3-9135-AA30B59CFEB5

Q34608317-177DA972-0359-48F1-8AEF-251304B7EC6C

Q34608317-218175EB-52F8-4C3A-9639-2C37F27E587C

Q34608317-22C4C9F3-9D50-4139-9177-70FE18F00EC9

Q34608317-3F71E824-3D7D-4165-A4B6-DC7278CAB9C8

Q34608317-48409493-4F6B-4B0E-A84C-46F8D1147BD3

Q34608317-4CD928B6-444E-4CB6-A5F4-125C10D476C0

P304

Q34608317-C934D8CB-B8EB-463F-8C18-583F1085729B

P31

Q34608317-B5EBF194-3796-4AC6-AAEE-CF01FEDA8DA1

P356

Q34608317-1D00E990-8777-4C18-A543-95E4D3CD423D

P407

Q34608317-A1C12AFB-9983-42E0-886A-6D57522523C7

P433

Q34608317-19895CE2-B8C0-4147-ABE9-C38709D2A7E4

P478

Q34608317-2EE92259-DE28-4FF7-8045-C21EE4534F7F

P50

Q34608317-B01409A0-0426-49C9-A504-4513D5410823

P577

Q34608317-979F57E6-E662-4E26-99E9-E250B9F0F22A

P698

Q34608317-996F5DC7-6345-4F86-AB5E-4A633D4D2C36

P921

Q34608317-3D863C63-5D94-4319-BB5D-820437EBD9FF

Q34608317-D441C1A8-37C7-46C0-9C8F-B7EDB1E30D48

P932

Q34608317-28EB5018-4BAD-4652-8565-00849BD15971

P356

P1433

Journal of Clinical Investigation

P1476

Aberrantly glycosylated IgA1 i ...... with restricted heterogeneity

@en

P2093

Bruce A Julian

http://www.w3.org/2001/XMLSchema#string

Hitoshi Suzuki

http://www.w3.org/2001/XMLSchema#string

James Robinson

http://www.w3.org/2001/XMLSchema#string

Jan Novak

http://www.w3.org/2001/XMLSchema#string

Jeannette Y Lee

http://www.w3.org/2001/XMLSchema#string

Jiri Mestecky

http://www.w3.org/2001/XMLSchema#string

Milan Tomana

http://www.w3.org/2001/XMLSchema#string

Rhubell Brown

http://www.w3.org/2001/XMLSchema#string

Run Fan

http://www.w3.org/2001/XMLSchema#string

Stacy Hall

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic generation of antibody diversity

Predominant autoantibody production by early human B cell precursors

Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy.

Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies

Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors.

The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions.

The mechanism and regulation of chromosomal V(D)J recombination.

Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy

Aberrant glycosylation in IgA nephropathy (IgAN).

IgA nephropathy: an update.

P304

1668-1677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI38468

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19478457

http://www.w3.org/2001/XMLSchema#string

P921

P932

2689118

http://www.w3.org/2001/XMLSchema#string